User profiles for "author:Hyung-Don Kim"

Hyung-Don Kim

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine
Verified email at amc.seoul.kr
Cited by 1325

[HTML][HTML] Korean practice guidelines for gastric cancer 2022: an evidence-based, multidisciplinary approach

TH Kim, IH Kim, SJ Kang, M Choi, BH Kim… - Journal of Gastric …, 2023 - ncbi.nlm.nih.gov
Gastric cancer is one of the most common cancers in Korea and the world. Since 2004, this
is the 4th gastric cancer guideline published in Korea which is the revised version of …

Association between expression level of PD1 by tumor-infiltrating CD8+ T cells and features of hepatocellular carcinoma

HD Kim, GW Song, S Park, MK Jung, MH Kim, HJ Kang… - Gastroenterology, 2018 - Elsevier
Background & Aims T-cell exhaustion, or an impaired capacity to secrete cytokines and
proliferate with overexpression of immune checkpoint receptors, occurs during chronic viral …

VEGF-A drives TOX-dependent T cell exhaustion in anti–PD-1–resistant microsatellite stable colorectal cancers

CG Kim, M Jang, Y Kim, G Leem, KH Kim, H Lee… - Science …, 2019 - science.org
Although immune checkpoint blockade therapies have demonstrated clinical efficacy in
cancer treatment, harnessing this strategy is largely encumbered by resistance in multiple …

Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival

HD Kim, YS Lim, S Han, J An, GA Kim, SY Kim, SJ Lee… - Gastroenterology, 2015 - Elsevier
Background & Aims Hepatocellular carcinoma (HCC) has a high rate of intrahepatic
recurrence after curative treatment, possibly because metastases are not always identified …

[HTML][HTML] Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma

S Chuah, J Lee, Y Song, HD Kim, M Wasser… - Journal of …, 2022 - Elsevier
Background & Aims While immune checkpoint blockade (ICB) has shown promise in
patients with hepatocellular carcinoma (HCC), it is associated with modest response rates …

[PDF][PDF] 4‐1BB Delineates Distinct Activation Status of Exhausted Tumor‐Infiltrating CD8+ T Cells in Hepatocellular Carcinoma

HD Kim, S Park, S Jeong, YJ Lee, H Lee, CG Kim… - …, 2020 - Wiley Online Library
Background and Aims Targeting costimulatory receptors with agonistic antibodies is a
promising cancer immunotherapy option. We aimed to investigate costimulatory receptor …

Immunological and clinical implications of immune checkpoint blockade in human cancer

HD Kim, SH Park - Archives of pharmacal research, 2019 - Springer
Immune checkpoint inhibitors (ICIs) such as anti-PD-1 and anti-CTLA-4 therapy are now
FDA-approved treatment options for different cancer types. However, the therapeutic efficacy …

TOX-expressing terminally exhausted tumor-infiltrating CD8+ T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer

HS Han, S Jeong, H Kim, HD Kim, AR Kim, M Kwon… - Cancer letters, 2021 - Elsevier
Exhausted T cells in the tumor microenvironment are major targets of immunotherapies.
However, the exhaustion status of CD8+ tumor-infiltrating lymphocytes (TILs) in bladder …

Lenvatinib versus Sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: an inverse probability of treatment weighting analysis

A Casadei‐Gardini, M Scartozzi, T Tada… - Liver …, 2021 - Wiley Online Library
Purpose Data from common clinical practice were used to generate balanced cohorts of
patients receiving either sorafenib or lenvatinib, for unresectable hepatocellular carcinoma …

PD-1 blockade-unresponsive human tumor-infiltrating CD8+ T cells are marked by loss of CD28 expression and rescued by IL-15

KH Kim, HK Kim, HD Kim, CG Kim, H Lee… - Cellular & Molecular …, 2021 - nature.com
Blockade of programmed death-1 (PD-1) reinvigorates exhausted CD8+ T cells, resulting in
tumor regression in cancer patients. Recently, reinvigoration of exhausted CD8+ T cells …